Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs

By D. V. Morrissey, Jennifer A. Lockridge, L. Shaw, Karin S. Blanchard, K. Jensen, Wendy Breen, Kim Hartsough, Lynn Machemer, S. Radka, V. Jadhav and 9 more. Nature Biotechnology, 2005

1,177 citations recorded by the source corpus.

Subfields: Epidemiology, Immunology, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/bb06b73a28c6b9b8a97b9fe4687e9b5f513cd722

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. John J. Rossi

In Immunology

1. Robert Langer
2. John J. Rossi

In Molecular Biology

1. John J. Rossi
2. P. McCray
3. Robert Langer
4. Peter S. Linsley
5. M. Manoharan
6. B. Davidson
7. L. Aagaard
8. Francis C. Szoka Jr.

Citations in the corpus

• Delivery of siRNA Therapeutics: Barriers and Carriers (2010, methodology): “This property has been used to target the siRNA delivery to the RES organs ( 32 ,33).”
• Current prospects for RNA interference-based therapies (2011, methodology): “For example, using 2′-O-methyl-modified purine nucleosides in the passenger strand reduces IFN induction but retains targeting specificity [38] [39] [40] .”
• Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application (2010, background): “Chemical modification of siRNA prevented non-specific inhibition of virus infection in a hepatitis B virus (HBV) model in vivo”
• siRNA delivery systems for cancer treatment. (2009, methodology): “The surfaces of SNALPs were coated with a polyethylene glycol–lipid conjugate that provides a neutral, hydrophilic, exterior and stabilizes the particle during formulation [43].”
• Lipid-based Nanoparticles for Nucleic Acid Delivery (2007, background): “This was attributed to the induction of an antibody against PEG that results from the strong adjuvant effect of the plasmid DNAYcationic lipid components in the SNALP (56).”
• A combinatorial library of lipid-like materials for delivery of RNAi therapeutics (2008, methodology): “Recently, systemic delivery of siRNA to the liver of mice and nonhuman primates was demonstrated using a lipid formulatio”
• Breaking down the barriers: siRNA delivery and endosome escape (2010, background): “A variety of approaches have been developed that promote siRNA delivery in vivo, including cationic nanoparticles (Morrissey et al., 2005), lipids and liposomes (Akinc et al.”
• RNAi therapeutics: principles, prospects and challenges. (2007, background): “Moreover, an in vivo model using 2'-F, 2'-O-methyl and 2'-H backbone modified siRNA against HBV have demonstrated that cytokine induction can be abrogated while maintaining silencing activity [56] Despite these promising result great care and thorough testing are clearly needed before proceeding to ”